TLDR
- Pulse Biosciences (PLSE) shares climbed 16.8% Tuesday following substantial insider purchases totaling $13.3 million.
- Co-Chairman Robert Duggan acquired 660,233 shares for approximately $13 million, with CEO Paul LaViolette adding 15,000 shares for roughly $295,000.
- Both transactions occurred through the company’s at-the-market equity offering program within an approved trading window.
- The medical technology company specializes in nanosecond pulsed field ablation technology designed for atrial fibrillation treatment.
- PLSE has climbed approximately 39% year-to-date and currently maintains a market capitalization of $1.3 billion.
Shares of Pulse Biosciences (PLSE) surged 16.8% during Tuesday’s trading session after the medical device company revealed that two key executives purchased a combined $13.3 million worth of company stock.
The significant purchases by Co-Chairman Robert Duggan and CEO Paul LaViolette took place on May 11, 2026, within the company’s approved trading window period.
At the time of publication, PLSE stock was trading approximately 13% higher, pushing its year-to-date performance to about 39%.
Duggan accounted for the bulk of the buying activity, acquiring 660,233 shares for a total investment of roughly $13 million. LaViolette contributed with a purchase of 15,000 shares valued at approximately $295,350.
Combined, both executives accumulated 675,233 shares utilizing Pulse Biosciences’ at-the-market equity offering mechanism.
The ATM program provides the company flexibility to sell shares directly to the market. When company insiders use this mechanism to purchase rather than sell, it typically signals strong internal conviction about the company’s prospects.
Why the Insider Activity Stands Out
Insider buying of this magnitude is uncommon. A joint $13.3 million investment from two senior leaders represents the type of transaction that captures market attention and typically drives investor response.
The purchases arrive on the heels of the company’s first-quarter earnings report and updated data regarding its nPulse catheter technology.
Wall Street analysts delivered mixed assessments following these announcements. While there’s enthusiasm surrounding promising clinical results from European trials and an accelerated timeline for U.S. pivotal studies, questions persist regarding negligible revenue generation, expanding losses, and substantial cash expenditure.
Despite generating limited commercial revenue, Pulse Biosciences commands a market valuation of $1.3 billion.
What PLSE Actually Does
The company’s flagship technology leverages nanosecond pulsed field ablation — a method that delivers extremely brief electrical energy pulses to targeted cells while preserving adjacent tissue structures.
Pulse Biosciences primarily targets atrial fibrillation, a widespread cardiac arrhythmia condition.
The company has emphasized efforts to expedite its U.S. regulatory pathway, with encouraging feasibility data from European studies serving as a positive indicator according to industry analysts.
PLSE’s average daily trading volume registers at approximately 294,600 shares. Current technical analysis indicators display a “Strong Buy” signal.
TipRanks’ AI model assigns PLSE a Neutral rating overall, acknowledging weak financial metrics balanced against a healthy balance sheet and advancing clinical pipeline.
With a year-to-date gain approaching 39%, the stock is significantly outperforming broader market indices as 2026 reaches its midpoint.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
